Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, October 3, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Serge Belanger Downgraded (VRCA) to Hold and Held Target at $12 on, Oct 3rd, 2024
Serge Belanger of Needham, Downgraded "Verrica Pharmaceuticals Inc." (VRCA) to Hold and Held Target at $12 on, Oct 3rd, 2024.
Serge has made no other calls on VRCA in the last 4 months.
There are 2 other peers that have a rating on VRCA. Out of the 2 peers that are also analyzing VRCA, 1 agrees with Serge's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Kemp Dolliver of "Brookline Capital" Downgraded from Strong Buy to Hold on, Wednesday, October 2nd, 2024
This is the rating of the analyst that currently disagrees with Serge
- Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $13 on, Thursday, August 15th, 2024
